As2O3 induces apoptosis in human hepatocellular carcinoma HepG2 cells through a ROS-mediated mitochondrial pathway and activation of caspases

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 2, 2015, Pages 2190-2196

  Jiang, Lin ^a   Wang, Le ^a   Chen, Lei ^a   Cai, Guo Hong ^a   Ren, Qin You ^a   Chen, Jian Zong ^b   Shi, Heng Jun ^a   Xie, Yong Hong ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Caspase; Hepatocellular carcinoma; Mitochondrial pathway; Reactive oxygen species

Indexed keywords

ARSENIC TRIOXIDE; CASPASE; CASPASE 3; CASPASE 6; CASPASE 9; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL COUNT; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MTT ASSAY; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84926361584     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Laing ST, Lemoy MJ, Sammak RL, Tarara RP. Metastatic hepatocellular carcinoma in a juvenile rhesus macaque (Macaca mulatta). Comp Med 2013; 63: 448-53.
2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237-57.
3. Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett 2013; 6: 821-28. 4.
4. Memon K, Kulik L, Lewandowski RJ, Gupta R, Ryu RK, Miller FH, Vouche M, Atassi R, Ganger D, Mulcahy MF, Salem R. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials. J Vasc Interv Radiol 2013; 24: 1189-97. e2.
5. Chan JY, Siu KP, Fung KP. Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells. Cancer Lett 2006; 236: 250-8.
6. Park MJ, Kim YK, Park HJ, Hwang J, Lee WJ. Scirrhous hepatocellular carcinoma on gadoxetic Acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 2013; 37: 872-81.
7. Fu ZC, Zhang B, Fu ZJ. As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland. Med Hypotheses 2010; 75: 490-1.
8. Novick SC, Warrell RP Jr. Arsenicals in hematologic cancers. Semin Oncol 2000; 27: 495-501.
9. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 2002; 71: 275-85.
10. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-61.
11. Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, Hu L, Wang S, Zhao Y, Li X, Zhang Y, Fan S, Lv C, Li Y, Su Y, Zhao H, Zhang X, Zhou J. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 2013; 119: 115-25.
12. Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA. Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther 2013; 6: 75-84.
13. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-7.
14. Aune TM, Pogue SL. Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide. J Clin Invest 1989; 84: 863-75.
15. Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, Habermehl GG. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha. Biochem J 1989; 263: 539-45.
16. Shaughnessy SG, Buchanan MR, Turple S, Richardson M, Orr FW. Walker carcinosarcoma cells damage endothelial cells by the generation of reactive oxygen species. Am J Pathol 1989; 134: 787-96.
17. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51: 794-8.
18. Fang J, Sawa T, Akaike T, Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res 2002; 62: 3138-43.
19. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-5.
20. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998; 55: 1747-58.
21. Crompton M, Barksby E, Johnson N, Capano M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 2002; 84: 143-52.
22. Ma Y, Ogino T, Kawabata T, Li J, Eguchi K, Okada S. Cupric nitrilotriacetate-induced apoptosis in HL-60 cells association with lipid peroxidation, release of cytochrome C from mitochondria, and activation of caspase-3. Free Radic Biol Med 1999; 27: 227-33.
23. Antonsson B, Montessuit S, Lauper S, Eskes R, Martinou JC. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 2000; 345 Pt 2: 271-8.
24. Atlante A, Calissano P, Bobba A, Azzariti A, Mar-ra E, Passarella S. Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J Biol Chem 2000; 275: 37159-66.
25. Bossy-Wetzel E, Green DR. Assays for cytochrome c release from mitochondria during apoptosis. Methods Enzymol 2000; 322: 235-42.
26. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.
27. Denault JB, Boatright K. Apoptosis in Bio-chemistry and Structural Biology. 3-8 February 2004, Keystone, CO, USA. IDrugs 2004; 7: 315-7.
28. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
29. Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999; 274: 17941-5.